Telomir Pharmaceuticals, Inc. Common Stock (TELO) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Earnings Overview
As of June 21, 2026, Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported trailing twelve-month net income of -$9M, reflecting +41.1% year-over-year growth. The company earned $-0.27 per diluted share over the past four quarters.
Looking at the long-term picture, TELO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$138,131 in fiscal 2021.
Telomir Pharmaceuticals, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TARA (-$63M net income), ADTX (-$52M net income, -1305608.8% margin), AEYE (-$4M net income, -7.6% margin), TELO has comparable earnings metrics. Compare TELO vs TARA →
TELO Earnings vs Peers
Earnings metrics vs comparable public companies
TELO Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$10M | +37.0% | -$11M | $-0.33 | - | - |
| 2024 | -$17M | -26.5% | -$12M | $-0.56 | - | - |
| 2023 | -$13M | -1430.4% | -$4M | $-0.44 | - | - |
| 2022 | $-854,147 | -518.4% | $-854,147 | $-0.03 | - | - |
| 2021 | $-138,131 | - | $-138,131 | $-0.00 | - | - |
Download Data
Export TELO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TELO — Frequently Asked Questions
Quick answers to the most common questions about buying TELO stock.
What is TELO earnings per share (EPS)?
TELO trailing twelve-month (TTM) diluted EPS is $-0.27, reflecting +41.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Telomir Pharmaceuticals, Inc. Common Stock's net income?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) trailing twelve-month net income is $-9M as of 2025. Earnings grew +41.1% year-over-year.
Is TELO profitable?
TELO is not currently profitable on a TTM basis, reporting a net loss of $-9M. Net margin is N/A. Investors should monitor for a return to profitability.
What is TELO's earnings growth rate?
TELO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are TELO's profit margins?
Telomir Pharmaceuticals, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -317.6%.
Is TELO growing earnings?
Yes, TELO earnings are accelerating — EPS growth of +41.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-9M. Earnings momentum is strengthening.
What was TELO's best earnings year?
Telomir Pharmaceuticals, Inc. Common Stock's highest annual net income on record is $-138131.00, achieved in fiscal year 2021. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were TELO's earnings last quarter?
TELO's most recent reported quarter was Q1 2026. Net income was $-990947.00 with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.